Esperion Therapeutics Inc - Asset Resilience Ratio

Latest as of December 2023: 0.00%

Esperion Therapeutics Inc (ESPR) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Esperion Therapeutics Inc (ESPR) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$0.00

Cash + Short-term Investments

Total Assets

$205.80 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2002–2023)

This chart shows how Esperion Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Esperion Therapeutics Inc balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Esperion Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ESPR long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$0.00	0%
Total Liquid Assets	$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Esperion Therapeutics Inc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Esperion Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Esperion Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Kamada TA:KMDA	Drug Manufacturers - Specialty & Generic	0.00%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Yipinhong Pharmaceutical Co Ltd Class A SHE:300723	Drug Manufacturers - Specialty & Generic	1.01%
Avadel Pharmaceuticals PLC NASDAQ:AVDL	Drug Manufacturers - Specialty & Generic	5.90%

Annual Asset Resilience Ratio for Esperion Therapeutics Inc (2002–2023)

The table below shows the annual Asset Resilience Ratio data for Esperion Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.00%	$0.00	$205.80 Million	--
2022-12-31	16.97%	$42.09 Million	$247.94 Million	+3.76pp
2021-12-31	13.22%	$50.44 Million	$381.59 Million	--
2020-12-31	0.00%	$0.00	$353.26 Million	--
2019-12-31	16.16%	$34.65 Million	$214.45 Million	-52.89pp
2018-12-31	69.05%	$99.05 Million	$143.45 Million	+9.40pp
2017-12-31	59.65%	$165.73 Million	$277.83 Million	-11.07pp
2016-12-31	70.72%	$173.42 Million	$245.21 Million	+25.07pp
2015-12-31	45.65%	$134.93 Million	$295.57 Million	+31.14pp
2014-12-31	14.51%	$20.80 Million	$143.34 Million	+10.01pp
2013-12-31	4.50%	$3.53 Million	$78.29 Million	-3.97pp
2002-12-31	8.47%	$4.35 Million	$51.41 Million	--

pp = percentage points

About Esperion Therapeutics Inc

NASDAQ:ESPR USA Drug Manufacturers - Specialty & Generic

Market Cap

$760.22 Million

Market Cap Rank

#10427 Global

#2778 in USA

Share Price

$3.18

Change (1 day)

+0.00%

52-Week Range

$1.91 - $4.08

All Time High

$80.76